Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Evotec Reports Second Multi-Target Collaboration With UCB

Oct. 5 (Bloomberg) -- Evotec AG entered into a second multi-year, multi-target drug discovery cooperation with UCB SA in the field of immunology. Evotec will identfy small molecules against a selected number of targets.

Evotec will receive research funding based on the resource allocated over the projects and will be further rewarded on achieving the goals with early stage discovery, preclinical and clinical milestones. Evotec will also receive royalties based on net sales of any approved drugs.

Link to Statement:{NSN LSKVAU3PR6RK <GO>}

Link to Company News:{EVT GR <Equity> CN <GO>} Link to Company News:{UCB BB <Equity> CN <GO>}

To contact the editor responsible for this story: Mariajose Vera at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.